ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,548.65
      1.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Compugen Ltd (CGEN)

      7. Compugen Ltd (CGEN) News

      CGEN

      Compugen (CGEN)

      Compugen Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CGEN
      DateTimeSourceHeadlineSymbolCompany
      04/25/20247:00AMPR Newswire (US)Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024NASDAQ:CGENCompugen Ltd
      04/10/20247:00AMPR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503NASDAQ:CGENCompugen Ltd
      04/03/20247:00AMPR Newswire (US)Compugen to Participate in Two Upcoming Investor ConferencesNASDAQ:CGENCompugen Ltd
      03/11/20247:00AMPR Newswire (US)Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer ImmunotherapyNASDAQ:CGENCompugen Ltd
      03/06/20247:00AMPR Newswire (US)Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024NASDAQ:CGENCompugen Ltd
      03/05/20244:06PMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:CGENCompugen Ltd
      03/05/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      03/05/20247:00AMPR Newswire (US)Compugen Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:CGENCompugen Ltd
      03/05/20246:05AMIH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:CGENCompugen Ltd
      02/26/20247:00AMPR Newswire (US)Compugen to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:CGENCompugen Ltd
      02/20/20247:00AMPR Newswire (US)Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024NASDAQ:CGENCompugen Ltd
      02/15/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      02/15/20247:00AMPR Newswire (US)Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical OfficerNASDAQ:CGENCompugen Ltd
      01/08/20247:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      01/08/20247:05AMPR Newswire (US)Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerNASDAQ:CGENCompugen Ltd
      01/08/20247:00AMPR Newswire (US)Compugen Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CGENCompugen Ltd
      12/19/20239:30AMAllPennyStocks.comStrong Open For Biotech Following Exclusive Agreement AnnouncementNASDAQ:CGENCompugen Ltd
      12/19/20237:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      12/19/20237:10AMPR Newswire (US)Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerNASDAQ:CGENCompugen Ltd
      12/19/20237:05AMPR Newswire (US)Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 BiologyNASDAQ:CGENCompugen Ltd
      12/19/20237:00AMBusiness WireGilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramNASDAQ:CGENCompugen Ltd
      11/07/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      11/07/20237:00AMPR Newswire (US)Compugen Reports Third Quarter 2023 ResultsNASDAQ:CGENCompugen Ltd
      11/06/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      11/06/20237:00AMPR Newswire (US)Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to ImmunotherapyNASDAQ:CGENCompugen Ltd
      11/03/20234:35PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
      11/03/20234:35PMPR Newswire (US)Compugen Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:CGENCompugen Ltd
      10/31/20239:00AMPR Newswire (US)Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating CancerNASDAQ:CGENCompugen Ltd
      10/24/20237:00AMPR Newswire (US)Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023NASDAQ:CGENCompugen Ltd
      10/03/20237:00AMPR Newswire (US)Compugen to Present at Single Cell Genomics 2023 MeetingNASDAQ:CGENCompugen Ltd
       Showing the most relevant articles for your search:NASDAQ:CGEN